Federal Cannabis Rescheduling: Evidence-Based Policy Over Celebrity Opinion
The debate over federal cannabis rescheduling requires evidence-based policy decisions rather than celebrity-driven discourse. Current Schedule I classification restricts vital clinical research and creates legal barriers that complicate patient access…
SubscriberWrites: From Shiva to Science: India’s Uneasy Relationship with Cannabis
India cannabis policy changes reflect a complex balance between tradition and modern science. Understanding these changes is crucial for clinicians treating diverse patient populations. This update highlights emerging regulatory shifts and their clinical…
Cannabinoids vs. Opioids: Exploration and Evolution of Pain Management
Cannabinoids pain management offers a promising alternative to traditional opioids. Research shows medicinal cannabis can reduce opioid consumption and improve patient outcomes. Understanding cannabinoids pain management is key to evolving future pain…
Synthetic cannabinoids cause more convulsion and hypothermia in mice than cannabis-derived cannabinoids.
Synthetic cannabinoids toxicity causes more convulsions and hypothermia in mice than cannabis-derived cannabinoids. This study compares effects of synthetic and endogenous cannabinoids on biological systems. Findings reveal synthetic cannabinoids…
Activation of a Cannabinoid Receptor Represents a Promising Therapeutic Strategy for Parkinson’s Disease
CB2 receptor agonist Parkinsons shows promise as a therapeutic strategy by promoting neuroprotection and motor function recovery. The agonist AM1241 activates CB2 receptors to increase dopaminergic neuron survival. This mechanism involves the…
